enGene Therapeutics Warrants (ENGNW) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 113 193 sessions, September 23, 2025 to September 23, 2026
- Largest daily move
- +215.7% close of October 15, 2025
- 1-year change
- -60.5% closing prices, September 23, 2025 to September 23, 2026
Company Description
enGene Therapeutics Warrants (NASDAQ: ENGNW) is classified in the biological products, (no diagnostic substances) industry.
ENGNW has declined 60.5% over the past year. The last closing price was $0.3400.
For FY2025, enGene Therapeutics Warrants reported net income of -$117.3M and diluted earnings per share of $2.29.
This page collects what Stock Titan holds for ENGNW, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
enGene Therapeutics Warrants (ENGNW) closed at $0.3400 on September 23, 2026. Over the past 12 months, the price has lost 60.5%.
ENGNW Metrics & Rankings
Price returns through September 23, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
enGene Therapeutics Warrants has 2 recent news articles. Of the recent coverage, 0 articles coincided with positive price movement and 1 with negative movement. Key topics include management. View all ENGNW news →
SEC Filings
enGene Therapeutics Warrants has filed 10 recent SEC filings, including 5 Form SCHEDULE 13G/A, 2 Form 3, 2 Form 8-K, 1 Form 10-Q. The most recent filing was submitted on September 8, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ENGNW SEC filings →
Financial Highlights
operating income reached -$123.2M, and net income was -$117.3M. Diluted earnings per share stood at $2.29. The company generated -$99.2M in operating cash flow. With a current ratio of 6.30, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in enGene Therapeutics Warrants (ENGNW) currently stands at 4.7 thousand shares, down 90.4% from the previous reporting period.
Days to Cover History
Days to cover for enGene Therapeutics Warrants (ENGNW) currently stands at 1.0 days, down 88.2% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 102.2 days.
ENGNW Company Profile & Sector Positioning
enGene Therapeutics Warrants (ENGNW) and is listed on the NASDAQ.
Investors comparing ENGNW often look at related companies in the same sector, including Aspire-Lakewood Holdings, Inc. Warrant (ASBPW), BioCardia, Inc. Warrant (BCDAW), BriaCell Therapeutics Corp. Warrant (BCTXW), BriaCell Therapeutics Corp. Warrant (BCTXZ), and Celularity Inc. Warrant (CELUW). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ENGNW's relative position within its industry.